These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 29575835)

  • 1. [The therapeutic effect of HSV1-hGM-CSF combined with doxorubicin on the mouse breast cancer model].
    Zhuang XF; Zhang SR; Liu BL; Wu JL; Li XQ; Gu HG; Shu Y
    Zhonghua Zhong Liu Za Zhi; 2018 Mar; 40(3):178-185. PubMed ID: 29575835
    [No Abstract]   [Full Text] [Related]  

  • 2. Doxorubicin-enriched, ALDH(br) mouse breast cancer stem cells are treatable to oncolytic herpes simplex virus type 1.
    Zhuang X; Zhang W; Chen Y; Han X; Li J; Zhang Y; Zhang Y; Zhang S; Liu B
    BMC Cancer; 2012 Nov; 12():549. PubMed ID: 23176143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Construction of a new oncolytic virus oHSV2hGM-CSF and its anti-tumor effects].
    Shi GL; Zhuang XF; Han XP; Li J; Zhang Y; Zhang SR; Liu BL
    Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):89-95. PubMed ID: 22780924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel oncolytic herpes simplex virus type 2 has potent anti-tumor activity.
    Zhao Q; Zhang W; Ning Z; Zhuang X; Lu H; Liang J; Li J; Zhang Y; Dong Y; Zhang Y; Zhang S; Liu S; Liu B
    PLoS One; 2014; 9(3):e93103. PubMed ID: 24671154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thalidomide suppressed the growth of 4T1 cells into solid tumors in Balb/c mice in a combination therapy with the oncolytic fusogenic HSV-1 OncdSyn.
    Israyelyan A; Shannon EJ; Baghian A; Kearney MT; Kousoulas KG
    Cancer Chemother Pharmacol; 2009 Nov; 64(6):1201-10. PubMed ID: 19308409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo anticancer synergy mechanism of doxorubicin and verapamil combination treatment is impaired in BALB/c mice with metastatic breast cancer.
    McCarthy M; Auda G; Agrawal S; Taylor A; Backstrom Z; Mondal D; Moroz K; Dash S
    Exp Mol Pathol; 2014 Aug; 97(1):6-15. PubMed ID: 24780744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.
    Liu BL; Robinson M; Han ZQ; Branston RH; English C; Reay P; McGrath Y; Thomas SK; Thornton M; Bullock P; Love CA; Coffin RS
    Gene Ther; 2003 Feb; 10(4):292-303. PubMed ID: 12595888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical evaluation of herpes simplex virus armed with granulocyte-macrophage colony-stimulating factor in pancreatic carcinoma.
    Liu H; Yuan SJ; Chen YT; Xie YB; Cui L; Yang WZ; Yang DX; Tian YT
    World J Gastroenterol; 2013 Aug; 19(31):5138-43. PubMed ID: 23964149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adaptation of transgene mRNA translation boosts the anticancer efficacy of oncolytic HSV1.
    Hoang HD; Said A; Vaidya N; Gilchrist VH; Malone K; Kabilan U; Topshee S; Xiang X; Yang AD; Olagnier D; Mossman K; Beug ST; Jafarnejad SM; Workenhe ST; Graber TE; Alain T
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36958764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic viral therapy with a combination of HF10, a herpes simplex virus type 1 variant and granulocyte-macrophage colony-stimulating factor for murine ovarian cancer.
    Goshima F; Esaki S; Luo C; Kamakura M; Kimura H; Nishiyama Y
    Int J Cancer; 2014 Jun; 134(12):2865-77. PubMed ID: 24265099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model.
    Lee JH; Roh MS; Lee YK; Kim MK; Han JY; Park BH; Trown P; Kirn DH; Hwang TH
    Cancer Gene Ther; 2010 Feb; 17(2):73-9. PubMed ID: 19629143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
    Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
    Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Xuanhusuo powder has an anti-breast cancer effect by inhibiting myeloid-derived suppressor cell differentiation in the spleen of mice through down-regulating granulocyte colony stimulating factor.
    Mao Y; Liu X; He K; Lin C; He B; Gao J
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Feb; 52(1):88-100. PubMed ID: 37283122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of mechanisms involved in the prevention of gamma irradiation-induced apoptosis by hGM-CSF.
    Liu R; Liu CB; Mohi MG; Arai K; Watanabe S
    Oncogene; 2000 Jan; 19(4):571-9. PubMed ID: 10698527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disabled infectious single-cycle herpes simplex virus as an oncolytic vector for immunotherapy of colorectal cancer.
    Todryk S; McLean C; Ali S; Entwistle C; Boursnell M; Rees R; Vile R
    Hum Gene Ther; 1999 Nov; 10(17):2757-68. PubMed ID: 10584922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.
    Hu JC; Coffin RS; Davis CJ; Graham NJ; Groves N; Guest PJ; Harrington KJ; James ND; Love CA; McNeish I; Medley LC; Michael A; Nutting CM; Pandha HS; Shorrock CA; Simpson J; Steiner J; Steven NM; Wright D; Coombes RC
    Clin Cancer Res; 2006 Nov; 12(22):6737-47. PubMed ID: 17121894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enforced granulocyte/macrophage colony-stimulating factor signals do not support lymphopoiesis, but instruct lymphoid to myelomonocytic lineage conversion.
    Iwasaki-Arai J; Iwasaki H; Miyamoto T; Watanabe S; Akashi K
    J Exp Med; 2003 May; 197(10):1311-22. PubMed ID: 12756267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus.
    Kohno SI; Luo C; Nawa A; Fujimoto Y; Watanabe D; Goshima F; Tsurumi T; Nishiyama Y
    Cancer Gene Ther; 2007 Nov; 14(11):918-26. PubMed ID: 17693992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective treatment of human breast tumor in a mouse xenograft model with herpes simplex virus type 1 specifying the NV1020 genomic deletion and the gBsyn3 syncytial mutation enabling high viral replication and spread in breast cancer cells.
    Israyelyan AH; Melancon JM; Lomax LG; Sehgal I; Leuschner C; Kearney MT; Chouljenko VN; Baghian A; Kousoulas KG
    Hum Gene Ther; 2007 May; 18(5):457-73. PubMed ID: 17536976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral immune responses induced by anti-idiotypic antibody fusion protein of 6B11scFv/hGM-CSF in BALB/c mice.
    Chang XH; Ye X; Cui H; Feng J; Li Y; Zhu HL; Yang WL; Fu TY; Cheng HY; Guo HF
    Chin Med J (Engl); 2006 Jan; 119(2):131-9. PubMed ID: 16454995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.